-
Patients taking AstraZeneca RA drug show partial improvement
NEW YORK — An experimental drug developed by AstraZeneca for rheumatoid arthritis produced mixed results in measurements of patients' conditions, according to results of a late-stage clinical trial.
AstraZeneca announced initial results of the phase-3 "OSKIRA-1" trial of fostamatinib, which it calls the first oral spleen tyrosine kinase inhibitor in development for RA.
-
GSK tests lupus drug in patients with inflammatory blood vessel disorder
LONDON — GlaxoSmithKline has started a late-stage clinical trial of a drug in patients with an inflammatory disease that affects the blood vessels.
The drug maker announced the start of a phase-3 trial of Benlysta (belimumab) in patients with vasculitis, a condition in which the body's immune system attacks blood vessels, leading to inflammation, disruption of blood flow and possible damage to the organs. The drug is being tested in patients with a common form of the disease known as anti-neutrophil cytoplasmic antibodies-positive vasculitis.